OrthoPediatrics Corp. (NASDAQ:KIDS) General Counsel Sells $132,006.60 in Stock

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) General Counsel Daniel J. Gerritzen sold 5,310 shares of OrthoPediatrics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the transaction, the general counsel now directly owns 110,767 shares of the company's stock, valued at approximately $2,753,667.62. This trade represents a 4.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

OrthoPediatrics Price Performance

KIDS stock traded down $0.57 during midday trading on Friday, reaching $24.97. The company had a trading volume of 299,893 shares, compared to its average volume of 162,897. The company has a market capitalization of $606.45 million, a price-to-earnings ratio of -20.30 and a beta of 1.22. The stock has a 50 day moving average price of $24.85 and a 200-day moving average price of $25.48. OrthoPediatrics Corp. has a 1-year low of $21.02 and a 1-year high of $35.99. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. The business had revenue of $52.67 million during the quarter, compared to the consensus estimate of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same quarter in the previous year, the firm earned ($0.23) earnings per share. Equities research analysts expect that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus reduced their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, March 5th. Needham & Company LLC reissued a "buy" rating and issued a $42.00 target price on shares of OrthoPediatrics in a research report on Wednesday, March 5th. Finally, Truist Financial reduced their target price on shares of OrthoPediatrics from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Wednesday, December 18th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KIDS. Quarry LP acquired a new position in OrthoPediatrics in the third quarter valued at about $25,000. R Squared Ltd acquired a new position in OrthoPediatrics during the fourth quarter worth about $48,000. KLP Kapitalforvaltning AS acquired a new position in OrthoPediatrics during the fourth quarter worth about $79,000. BNP Paribas Financial Markets raised its stake in OrthoPediatrics by 125.1% during the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company's stock worth $94,000 after acquiring an additional 1,929 shares in the last quarter. Finally, Quantbot Technologies LP raised its stake in OrthoPediatrics by 42.2% during the third quarter. Quantbot Technologies LP now owns 5,773 shares of the company's stock worth $157,000 after acquiring an additional 1,712 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company's stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.